Plain-English translation of NCT06789172 on ClinicalTrials.gov ↗ · Source last updated ·
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is one of the first times this treatment has been tested in people.
This is a first-in-human trial testing a new oral medication called in patients with advanced solid tumors. The study will test this medication alone and also in combination with pembrolizumab, an existing immunotherapy drug that helps the body fight cancer. Researchers want to understand how safe this treatment is, what dose works best, and whether it can help shrink tumors.
Current treatments for many advanced cancers stop working or cause unacceptable side effects. This medication is designed to work on the immune system in a new way — by blocking certain proteins that tumors use to hide from your body's defenses — so researchers hope it may help patients whose cancers have stopped responding to other therapies.
You likely qualify if…
You likely don't qualify if…
You will take the medication by mouth as a pill at home on a set schedule over repeating 21-day cycles. You will have regular clinic visits for blood tests, imaging scans to measure your tumors, and check-ins about side effects. The study starts with smaller doses that gradually increase as safety is confirmed in earlier groups. Some participants will also have tumor biopsies (small tissue samples taken by needle) at the beginning and during treatment to help researchers understand how the medication is working.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
United States
Australia